Liposomes useful for drug delivery

1. A method of treatment comprising the parenteral administration of a therapeutically effective amount of a liposomal irinotecan pharmaceutical composition comprising irinotecan liposomes to a patient, the irinotecan liposomes comprising irinotecan sucrose octasulfate and one or more phospholipids with a total of 150-500 mg irinotecan base per mmol total liposome phospholipids to a patient.

2. The method of claim 1 , wherein the pharmaceutical composition is intravenously administered.

3. The method of claim 1 , wherein the irinotecan liposomes comprise one or more lipids and the molar ratio of the irinotecan to the one or more lipids in totality is about 0.02-5.

4. The method of claim 1 , wherein the irinotecan liposomes comprise one or more lipids and has a total of about 0.5 mg irinotecan per mg of total lipid in the liposome.

5. The method of claim 1 , wherein the irinotecan liposomes comprise one or more lipids and has a total of about 0.15 to 1.5 moles of irinotecan per mole of total lipid in the liposome.

6. The method of claim 1 , wherein the irinotecan liposomes comprise one or more lipids and has a ratio of about 0.8 mmol irinotecan per 1 g of total lipid in the liposome.

7. The method of claim 1 , wherein the irinotecan liposomes comprise one or more phospholipids and has a total of about 500 mg irinotecan per mmol of total phospholipid in the liposome.

8. The method of claim 1 , wherein the irinotecan liposomes comprise DSPC and cholesterol.

9. The method of claim 1 , wherein the irinotecan liposomes comprise DSPC, cholesterol and PEG-DSPE in a molar ratio of 3:2:0.015.

10. The method of claim 1 , wherein the irinotecan liposomes have a volume-averaged mean of the liposome size of about 110-120 nm determined by quasi-elastic light scattering (QELS) using Gaussian model.

11. The method of claim 1 , having at least one additional characteristic selected from the group consisting of:

a. the pharmaceutical composition is intravenously administered;

b. the liposome comprises one or more lipids and the molar ratio of the irinotecan to the one or more lipids in totality is about 0.2;

c. the irinotecan liposomes comprise one or more lipids and has a total of about 0.5 mg irinotecan per mg of total lipid in the liposome;

d. the irinotecan liposomes comprise one or more lipids and has a total of about 0.15 to 1.5 moles of irinotecan per mole of total lipid in the liposome;

e. the irinotecan liposomes comprise one or more lipids and has a ratio of about 0.8 mmol irinotecan per 1 g of total lipid in the liposome;

f. the irinotecan liposomes comprise one or more phospholipids and has a total of about 500 mg irinotecan per mmol of total phospholipid in the liposome;

g. the irinotecan liposomes comprise DSPC and cholesterol;

h. the irinotecan liposomes comprise DSPC, cholesterol and PEG-DSPE in a molar ratio of 3:2:0.015;

i. the liposome is about 110-120 nm;

j. the irinotecan liposomes comprise about 1.25-2.42 mol irinotecan per g of lipid; and

k. at least 90% of the irinotecan in the pharmaceutical composition is encapsulated in the irinotecan liposomes.

12. A method of treatment comprising the parenteral administration of a therapeutically effective amount of an irinotecan liposome pharmaceutical composition to a patient, the irinotecan liposome pharmaceutical composition comprising irinotecan sucrose octasulfate encapsulated in a liposome comprising DSPC, cholesterol and PEG2000-DSPE in a molar ratio of 3:2:0.015, with about 0.15 to 1.5 moles of irinotecan per mole of total lipid in the liposome.

13. The method of claim 12 , wherein the liposome has a volume-averaged mean of the liposome size of about 110-120 nm determined by quasi-elastic light scattering (QELS) using Gaussian model.

14. The method of claim 12 , wherein the liposome has a total of about 500 mg irinotecan per mmol total phospholipid in the liposome.

15. The method of claim 12 , wherein at least 90% of the irinotecan in the pharmaceutical composition is encapsulated in the liposomes.

16. The method of claim 12 , wherein the liposome has a total of about 0.5 moles of irinotecan per mole of total lipid in the liposome.

17. The method of claim 12 , having at least one additional characteristic selected from the group consisting of:

a. the pharmaceutical composition is intravenously administered;

b. the molar ratio of the irinotecan to the one or more lipids in totality is about 0.02- 5 ;

c. the liposome comprises one or more lipids and has a total of about 0.5 mg irinotecan per mg of total lipid in the liposome;

d. the liposome comprises one or more lipids and has a total of about 0.15 to 1.5 moles of irinotecan per mole of total lipid in the liposome;

e. the liposome comprises one or more lipids and has a ratio of about 0.8 mmol irinotecan per 1 g of total lipid in the liposome;

f. the liposome comprises one or more phospholipids and has a total of about 500 mg irinotecan per mmol of total phospholipid in the liposome;

g. the liposome is about 110-120 nm; and

h. the liposome comprises about 1.25-2.42 mol irinotecan per g of lipid.

18. A method of treatment comprising the intravenous administration of a therapeutically effective amount of an irinotecan liposome pharmaceutical composition to a patient, the irinotecan liposome pharmaceutical composition comprising irinotecan and sucrose octasulfate encapsulated in a liposome comprising DSPC, cholesterol and PEG2000-DSPE in a molar ratio of 3:2:0.015, with a total of about 0.5 moles irinotecan per mole of total lipid in the liposome, and a total of about 500 mg irinotecan per mmol total phospholipid in the liposome.

19. The method of claim 18 , wherein at least 90% of the irinotecan in the pharmaceutical composition is encapsulated in the liposomes.

20. The method of claim 19 , wherein the liposome has a volume-averaged mean of the liposome size of about 110-120 nm determined by quasi-elastic light scattering (QELS) using Gaussian model.